|
Device
|
MARS
|
Prometheus
|
MARS
|
SPAD
|
ADVOS
|
|
Patients’ characteristics
|
|
Clinical setting
|
19 ICUs
|
10 ICUs
|
Surgical ICU
|
Medical ICU
|
|
Type of LF
| | | | |
|
- ACLF
|
100%
|
100%
|
56%
|
64%
|
|
- ALF
|
-
|
-
|
28%
|
-
|
|
- “secondary” LF
|
-
|
-
|
-
|
36%
|
|
- Graft failure
|
-
|
-
|
16%
|
-
|
|
(CLIF)-SOFA
|
8 ± 3
|
10 ± 3
|
13 ± 4
|
15 ± 3
|
|
MELD
|
26 ± 8
|
28 ± 10
| |
34 ± 7
|
|
Child-Pugh
|
11 ± 2
|
12 ± 1
| |
12 ± 1
|
|
Efficacy analysis
|
|
No. of treatments for efficacy analysis
|
4
|
8 (mean)
|
2.2 (mean)
|
2.2 (mean)
|
1
|
|
Delta-Bilirubin relative
|
−26% (day 4)
|
−23% (day 28)
|
−23%
|
−23%
|
−32%
|
|
Delta-Bilirubin absolute [mg/dL]
|
−8.7 (day 4)
|
−6 (day 28)
|
−4.3
|
−4.2
|
−8.3
|
|
Delta-creatinine relative
|
−20% (day 4)
|
−13% (day 28)
|
−18%
|
+5%
|
−27%
|
|
Delta-creatinine absolute [mg/dL]
|
−0.3 (day 4)
|
−0.2 (day 28)
|
−0.4
|
+0.1
|
−0.6
|
|
Delta-BUN relative
|
n.d.
|
n.d.
|
−9%
|
+5%
|
−37%
|
|
Delta-BUN absolute [mg/dL]
|
n.d
|
n.d.
|
−12
|
+8
|
−18
|
|
Maximum number of treatments
|
10
|
11
|
4
|
4
|
101
|
